ORCHESTRA BIOMED HOLDINGS IN (OBIO) Stock News

USA - Nasdaq - NASDAQ:OBIO - US68572M1062 - Common Stock

4.51 USD

-0.06 (-1.31%)

Last: 12/12/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

OBIO Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting

7 days ago - By: Orchestra BioMed Holdings, Inc. - Mentions: MDT

Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting

19 days ago - By: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

19 days ago - By: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Orchestra BioMed Holdings, Inc.

Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

a month ago - By: Orchestra BioMed Holdings, Inc.

Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

a month ago - By: Zacks Investment Research - Mentions: CLSD

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Beats Revenue Estimates

a month ago - By: Orchestra BioMed Holdings, Inc. - Mentions: LGND MDT

Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

a month ago - By: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

a month ago - By: Zacks Investment Research - Mentions: ADCT

ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates

a month ago - By: Zacks Investment Research - Mentions: ZYME

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

a month ago - By: Orchestra BioMed Holdings, Inc.

Orchestra BioMed to Host Business Update Call on November 12, 2025

2 months ago - By: Orchestra BioMed Holdings, Inc.

Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements

2 months ago - By: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial

2 months ago - By: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial

2 months ago - By: Benzinga - Mentions: ONMD ANVS XBIO PTGX ...

12 Health Care Stocks Moving In Friday's Intraday Session

2 months ago - By: Orchestra BioMed Holdings, Inc.

Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit

2 months ago - By: Orchestra BioMed Holdings, Inc. - Mentions: MDT

Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit

3 months ago - By: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout

3 months ago - By: Orchestra BioMed Holdings, Inc. - Mentions: MDT

Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout

4 months ago - By: Benzinga - Mentions: EPIX WORX THAR NLSP ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

4 months ago - By: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology

4 months ago - By: Orchestra BioMed Holdings, Inc. - Mentions: MDT

Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology

4 months ago - By: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction

4 months ago - By: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction

4 months ago - By: Zacks Investment Research - Mentions: GBIO

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Beats Revenue Estimates

4 months ago - By: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

4 months ago - By: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

4 months ago - By: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility

4 months ago - By: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility

4 months ago - By: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings

4 months ago - By: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings

4 months ago - By: Zacks Investment Research - Mentions: CRSP

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates

5 months ago - By: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Announces Pricing of $40 Million Public Offering

5 months ago - By: Orchestra BioMed Holdings, Inc.

Orchestra BioMed Announces Pricing of $40 Million Public Offering